Ever Supreme Bio Technology Co. Ltd (6712) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Ever Supreme Bio Technology Co. Ltd TWD 178, price TWD 160, upside +11.7%, quality 85 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ever Supreme Bio Technology Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 101.49 TWD – 509.42 TWD · fair‑value band 101.47 TWD – 339.78 TWD · the 159.50 TWD price screens below the 178.20 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Ever Supreme Bio Technology Co. in your weekly email
Every Wednesday you see whether Ever Supreme Bio Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments.
Show more
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; chimeric antigen receptor immune cells, a chimeric antigen receptor immune cells product; and allogeneic bone-marrow stem cells, used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. In addition, the company develops allogeneic umbilical cord mesenchymal stem cells (UMSC01), used to treat cardiovascular diseases and strokes. Further, it engages in the sale of other health products and related businesses; and cell preparations and investment activities in biotechnology and medical industry businesses. Ever Supreme Bio Technology Co., Ltd was incorporated in 2016 and is based in Taichung, Taiwan.
Stock analysis
Ever Supreme Bio Technology Co. Ltd (6712) currently trades at 159.50 TWD, while our model-based Fair Value estimate is 178.20 TWD, implying the stock looks roughly 10.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 198.54 TWD per share, and 2 of the 24 models we run sit above the 159.50 TWD price.
Bear case: the Economic Profit group reads lowest at 34.56 TWD, and 22 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 101.47 TWD (bear) to 339.78 TWD (bull), the price of 159.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 85/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Ever Supreme Bio Technology Co. Ltd reported revenue of 1.0B TWD in FY2025 versus 439M TWD in FY2021, a compound +23.4%/yr. Reported net income was 429M TWD in FY2025, compounding +3.8%/yr from FY2021.
Key figures
Market cap 16.2B TWD (≈ $510M) · P/E ratio 32.4 · P/S ratio 13.7 · EPS (TTM) 4.92 TWD · Dividend yield 2.1% · Net margin 42.2% · Return on equity 23.4% · Return on assets (EBIT) 21.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 69% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 12%, 6712 screens cheaper than that median.
Fair Value models
Bear 101.47 TWDFair Value 178.20 TWDBull 339.78 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.17 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+70.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.0%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−194% → 43%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +12.6% a year for the price.
Compare Ever Supreme Bio Technology Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score85 · Top 25%
Fair Value upside+10% · Top 25%
Profitability
Return on equity (TTM)23% · Top 25%
Return on assets11% · Top 25%
Net margin (TTM)44% · Top 25%
Operating margin (TTM)44% · Top 25%
Growth and dividend
Revenue growth23% · Above median
Dividend yield (TTM)2.1% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ever Supreme Bio Technology Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6712
Frequently asked questions
Is Ever Supreme Bio Technology Co. Ltd (6712) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 178.20 TWD versus a price of 159.50 TWD, about +12% upside (undervalued).
What is the fair value of 6712?
Our model-based fair value for Ever Supreme Bio Technology Co. Ltd is 178.20 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 159.50 TWD.
What is the quality score of 6712?
Ever Supreme Bio Technology Co. Ltd has a Quality Score of 85/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ever Supreme Bio Technology Co. Ltd (6712)?
Our model-based price target is the fair value of 178.20 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 101.47 TWD, optimistic scenario 339.78 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Ever Supreme Bio Technology Co. Ltd stock forecast for 2026?
Our models put fair value at 178.20 TWD, about +12% upside versus a price of 159.50 TWD (undervalued). Cautious scenario 101.47 TWD, optimistic scenario 339.78 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Ever Supreme Bio Technology Co. Ltd (6712)?
Ever Supreme Bio Technology Co. Ltd reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Sep 24, 2026).
Does Ever Supreme Bio Technology Co. Ltd pay a dividend?
Ever Supreme Bio Technology Co. Ltd currently shows a dividend yield of about 2.09% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Ever Supreme Bio Technology Co. Ltd (6712)?
For today's price to be fair in a discounted-cash-flow model, Ever Supreme Bio Technology Co. Ltd would have to grow free cash flow by +14.3 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +70.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 6712 use?
Our models discount Ever Supreme Bio Technology Co. Ltd at 10.3 %: a base by market capitalisation (small), damped by beta 0.30, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ever Supreme Bio Technology Co. Ltd that is +14.3 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Ever Supreme Bio Technology Co. Ltd (6712) delivered so far?
Over the past 5 years revenue at Ever Supreme Bio Technology Co. Ltd grew +70.5 % a year. The price currently implies +14.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ever Supreme Bio Technology Co. Ltd (6712) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Ever Supreme Bio Technology Co. Ltd (+14.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ever Supreme Bio Technology Co. Ltd (6712)?
The free-cash-flow yield on the price is 3.80 %: that much free cash flow Ever Supreme Bio Technology Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ever Supreme Bio Technology Co. Ltd (6712)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ever Supreme Bio Technology Co. Ltd it is 178.20 TWD per share (as of Sep 24, 2026), against a price of 159.50 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Ever Supreme Bio Technology Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6712 trades below its calculated fair value: price 159.50 TWD, fair value 178.20 TWD, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6712?
No. The price is what the market pays today (159.50 TWD); the fair value is what the company's own numbers justify (178.20 TWD). For Ever Supreme Bio Technology Co. Ltd the two are 18.70 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Ever Supreme Bio Technology Co. Ltd worth?
The market values Ever Supreme Bio Technology Co. Ltd at about 16.2B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 159.50 TWD; our models calculate a fair value of 178.20 TWD per share.
What do the bullish and bearish scenarios say about 6712?
Our models span a range for Ever Supreme Bio Technology Co. Ltd: cautious scenario 101.47 TWD, base 178.20 TWD, optimistic 339.78 TWD per share (as of Sep 24, 2026, price 159.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6712?
Ever Supreme Bio Technology Co. Ltd trades at a price-to-earnings ratio of 32.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 178.20 TWD is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 34.3 (reported for FY2025: 32.5). Other multiples: P/B 10.6, P/S 15.0, EV/EBITDA 32.8.
How solid is the balance sheet of Ever Supreme Bio Technology Co. Ltd (6712)?
Balance-sheet figures for Ever Supreme Bio Technology Co. Ltd (as of Sep 24, 2026): return on equity 23.4%. They feed the Quality Score of 85/100, which measures business quality independently of the share price.
How far is 6712 from its 52-week high?
Ever Supreme Bio Technology Co. Ltd trades at 159.50 TWD, about 69% below its 52-week high of 509.42 TWD and 30% above the low of 122.38 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 178.20 TWD is for.
Which stocks are comparable to Ever Supreme Bio Technology Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ever Supreme Bio Technology Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 159.50 TWD, calculated fair value 178.20 TWD (+12%), Quality Score 85/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6712 calculated?
We run Ever Supreme Bio Technology Co. Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 178.20 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Ever Supreme Bio Technology Co. Ltd currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ever Supreme Bio Technology Co. Ltd (6712)?
The closing price on Sep 24, 2026 was 159.50 TWD. Our model-based fair value is 178.20 TWD, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ever Supreme Bio Technology Co. Ltd right now?
The model range is unusually wide (101.47 TWD to 339.78 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Ever Supreme Bio Technology Co. Ltd
How large is the market capitalisation of Ever Supreme Bio Technology Co. Ltd (6712)?
The market capitalisation of Ever Supreme Bio Technology Co. Ltd is 16.2B TWD (≈ $510M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ever Supreme Bio Technology Co. Ltd (6712)?
The price-to-sales ratio of Ever Supreme Bio Technology Co. Ltd is 13.7 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ever Supreme Bio Technology Co. Ltd (6712)?
Earnings per share at Ever Supreme Bio Technology Co. Ltd are 4.92 TWD (price ÷ EPS = P/E 32.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ever Supreme Bio Technology Co. Ltd (6712)?
The dividend yield of Ever Supreme Bio Technology Co. Ltd is 2.1% (payout 67.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ever Supreme Bio Technology Co. Ltd (6712)?
The net margin of Ever Supreme Bio Technology Co. Ltd is 42.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ever Supreme Bio Technology Co. Ltd (6712)?
The return on equity (ROE) of Ever Supreme Bio Technology Co. Ltd is 23.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ever Supreme Bio Technology Co. Ltd (6712)?
On an EBIT basis the return on assets of Ever Supreme Bio Technology Co. Ltd is 21.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ever Supreme Bio Technology Co. Ltd (6712)?
The operating margin of Ever Supreme Bio Technology Co. Ltd is 44.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ever Supreme Bio Technology Co. Ltd (6712)?
Revenue at Ever Supreme Bio Technology Co. Ltd is growing +23.1% versus a year earlier (3y avg +17.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ever Supreme Bio Technology Co. Ltd (6712)?
Earnings per share at Ever Supreme Bio Technology Co. Ltd are growing −8.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ever Supreme Bio Technology Co. Ltd (6712) hold?
Ever Supreme Bio Technology Co. Ltd holds more cash than debt, 331M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Ever Supreme Bio Technology Co. Ltd in the live analysis
One click puts Ever Supreme Bio Technology Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
